People with a high body weight living in England can now access subsidised weight-loss drugs to treat their obesity.

Consumer Reports warns there are important considerations, especially for older adults, before starting these treatments.

Despite the continued success of GLP-1 drugs Ozempic and Wegovy, Novo Nordisk CEO Lars Fruergaard Jørgensen took a slight pay cut in 2024. He received 57.1 million Danish kroner (DKK) – $8 million – ...

The number of teens and young adults taking GLP-1 drugs has increased by 594 percent—but scientists are still trying to ...

Today we'll look at six European stocks that could continue outperforming in 2025. Some of these companies are available to ...

The MHRA reveals a staggering rise in deaths linked to weight loss and diabetes medications in the UK, with concerns over ...

The Indianapolis-based pharmaceutical company announced plans for four new manufacturing sites, but has not decided where ...

A lawsuit challenges the FDA's decision to remove semaglutide from the shortage list, alleging it was arbitrary and harms ...

We recently published an article titled Two of 10 Worst-Performing Stocks Fall to All-Time Lows on Tuesday. In this article, ...

When Trova Wine and Market in Dallas shut its doors last month after nearly five years in business, owner Michelle Bonds ...

A smart investment strategy is to diversify your portfolio with both stable, established companies and growth stocks. Growth ...

As high prices and supply issues drive consumers to alternative markets for GLP-1s, physicians aren’t too interested in using ...